Subcutaneous injection pain with C.E.R.A., a continuous erythropoietin receptor activator, compared with darbepoetin alfa

By Pannier Anne   Jordan Paul   Dougherty Frank C.   Bour Fabrice   Reigner Bruno  

Current Medical Research and Opinion, Vol. 23, Iss. 12, 2007-12 ,pp. : 3025-3032

Informa Healthcare

Access to resources Recommend Favorite

Evaluation of maintenance of stable haemoglobin levels in haemodialysis patients converting from epoetin or darbepoetin to monthly intravenous C.E.R.A.: the MIRACEL study

By Fliser D.   Kleophas W.   Dellana F.   Winkler R.E.   Backs W.   Kraatz U.   Fassbinder W.   Wizemann V.   Strack G.  

Current Medical Research and Opinion, Vol. 26, Iss. 5, 2010-05 ,pp. : 1083-1089

Informa Healthcare

Access to resources Recommend Favorite

Erythrocyte Indices in the Assessment of Iron Status in Dialysis-Dependent Patients with End-Stage Renal Disease on Continuous Erythropoietin Receptor Activator versus Epoetin β Therapy

By  

Acta Haematologica, Vol. 124, Iss. 1, 2010-07 ,pp. : 27-33

Karger

Access to resources Recommend Favorite

The effect of severe hepatic impairment on the pharmacokinetics and haematological response of C.E.R.A.

By Kupčová Viera   Šperl Jan   Pannier Anne   Jordan Paul   Dougherty Frank C.   Reigner Bruno  

Current Medical Research and Opinion, Vol. 24, Iss. 7, 2008-07 ,pp. : 1943-1950

Informa Healthcare

Access to resources Recommend Favorite

Comparing the efficacy of continuous erythropoietin receptor activator and darbepoetin Alfa treatments in Japanese patients with chronic kidney disease during the predialysis period: A propensity‐matched analysis

By  

NEPHROLOGY, Vol. 20, Iss. S4, 2015-12 ,pp. : 22-28

John Wiley & Sons Inc

Access to resources Recommend Favorite